Patent US4470975A successfully refreshed from Google Patents.
US4470975A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and composition for the elimination of water from an animal body
Assignee: HB BIOTECHNOLOGIES Corp
•
Filing: 1977-10-21
•
Granted: 1984-09-11
•
Expires: 1997-10-21
Abstract
Abstract It has been found that certain insoluble hydrophilic cross-linked polysaccharides are useful pharmaceutical agents in diverting water elimination from the renal route to the gastrointestinal route, and removing excess water from the body by the gastrointestinal route. These properties are of specific therapeutic value in the treatment of edema, water intoxication in chronic renal failure, in reducing the frequency of hemodialysis, and in the treatment of other forms of fluid retention such as congestive heart failure, cirrhosis of the liver, and other disorders associated with refractory swelling. Sephadex-brand insoluble hydrophilic, cross-linked dextrans are preferred in the practice of the invention.
Inventors
- 👤 Hillard Berger, deceased
- 👤 W. Gordon Walker
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 08:34
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
62 words
A method of treating edema in a host in need of such treatment because of renal failure which comprises orally administering to said host an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water in the lumen of the gastrointestinal tract and discharging the thus bound water by passage from the alimentary canal in the normal way.
Claim 2
Independent Claim
62 words
A method of treating edema in a host in need of such treatment because of renal failure which comprises orally administering to said host an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water in the lumen of the gastrointestinal tract and discharging the thus bound water by passage from the alimentary canal in the normal way.
Claim 3
Dependent Claim
104 words
A method according to claim 1 wherein said polysaccharide consists essentially of a copolymerization product in a gel grain form comprising a 3-dimensional macroscopic carbohydrate network, obtained from a neutral carbohydrate selected from the group consisting of dextran, sorbitol, starch, hydroxyethyl cellulose, dextrin, and sucrose and a bifunctional organic substance selected from the group consisting of epichlorohydrin, dichlorohydrin, diepoxybutane, bisepoxypropyl ether, ethylene glycol-bis-epoxypropyl ether, and 1,4-butan-diol-bis-epoxypropyl ether, bonded together by ether bridges of the general type --O--X--O-- wherein X representa an aliphatic radical containing from 3 to 10 carbon atoms, the said copolymerization product being water-insoluble but being capable of absorbing water with swelling.
Claim 4
Dependent Claim
77 words
A method according to claim 1 wherein said polysaccharide is a copolymerization product in gel grain form comprising a 3-dimensional macroscopic network of dextran substances, built-up of chains of mainly alpha-1,6-glucosidically bonded glucose residues, bonded together by ether bridges of the general type --R--O--X--O--R--, wherein R represents the dextram substances and X is an aliphatic radical containing from 3 to 10 carbon atoms, the said copolymerization product being water-insoluble but being capable of absorbing water with swelling.
Claim 5
Independent Claim
61 words
A method for treating obesity which comprises administering orally to a host in need of such treatment an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling in the lumen of the gastrointestinal tract, said oral administration being effective to eliminate the bound water via the gastro-intestinal route rather than by the renal route.
Claim 6
Independent Claim
61 words
A method for treating obesity which comprises administering orally to a host in need of such treatment an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling in the lumen of the gastrointestinal tract, said oral administration being effective to eliminate the bound water via the gastro-intestinal route rather than by the renal route.
Claim 7
Independent Claim
37 words
A method for treating edema in a mammal in need of such treatment which comprises administering orally to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling.
Claim 8
Independent Claim
37 words
A method for treating edema in a mammal in need of such treatment which comprises administering orally to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling.
Claim 9
Independent Claim
37 words
A method for treating obesity in a mammal in need of such treatment which comprises administering orally to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling.
Claim 10
Independent Claim
37 words
A method for treating obesity in a mammal in need of such treatment which comprises administering orally to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling.
Claim 11
Independent Claim
53 words
A method for reducing the frequency of dialysis to a mammal in need of such treatment because of renal failure which comprises orally administering to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling, and eliminating the bound water through the gastrointestinal route.
Claim 12
Independent Claim
53 words
A method for reducing the frequency of dialysis to a mammal in need of such treatment because of renal failure which comprises orally administering to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling, and eliminating the bound water through the gastrointestinal route.
References Cited (Backward Citations)
GB854715A
Cited
US3624209A
Cited
US3627872A
Cited
US4076930A
Cited
US3865807A
Cited
US3934007A
Cited
US3962429A
Cited
US3983232A
Cited
US4002173A
Cited
US4070460A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-09-11 | 1988-03-12 | 1988-09-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-09-11 | 1992-03-12 | 1992-09-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-09-11 | 1996-03-12 | 1996-09-11 | $7700.00 | Window Closed / Lapsed |